Medical Practice Confirms Clinical Trial Results of the Use of Intralesional Human Recombinant Epidermal Growth Factor in Advanced Diabetic FootUlcers

@article{LpezSaura2013MedicalPC,
  title={Medical Practice Confirms Clinical Trial Results of the Use of Intralesional Human Recombinant Epidermal Growth Factor in Advanced Diabetic FootUlcers},
  author={P. L{\'o}pez-Saura and Isis B Yera-Alos and C. Valenzuela-Silva and Odalys Gonz{\'a}lez-D{\'i}az and Amaurys del R{\'i}o-Mart{\'i}n and J. Berlanga-Acosta and Jos{\'e} I. Fern{\'a}ndez-Montequ{\'i}n and Boris Acevedo-Castro and Ernesto L{\'o}pez-Mola and Luis Herrera-Mart{\'i}nez},
  journal={Advances in Pharmacoepidemiology and Drug Safety},
  year={2013},
  volume={2},
  pages={1-9}
}
  • P. López-Saura, Isis B Yera-Alos, +7 authors Luis Herrera-Martínez
  • Published 2013
  • Medicine
  • Advances in Pharmacoepidemiology and Drug Safety
  • The intralesional injection of recombinant human epidermal growth factor (rhEGF) has been recently approved and introduced in several countries for the treatment of advanced diabetic foot ulcers (DFU), based on the results of five exploratory and one confirmatory, phase III clinical trials in 344 subjects. A significant stimulatory effect of this product on the healing process, given by development of granulation tissue and re-epithelization was shown in these trials, as well as a reduction in… CONTINUE READING
    17 Citations

    References

    SHOWING 1-10 OF 74 REFERENCES
    Effectiveness of recombinant human platelet‐derived growth factor for the treatment of diabetic neuropathic foot ulcers
    • 90
    Human epidermal growth factor enhances healing of diabetic foot ulcers.
    • 194
    • PDF